Bioxytran, Inc

Verastem Inc., based in Needham Heights, MA, is a biotechnology company specializing in the development of targeted therapies for RAS pathway-driven cancers. Known for its first-in-class RAF MEK clamp, avutometinib, the company is committed to providing innovative treatment options for patients facing aggressive cancers characterized by mutations in the RAS gene family. With a focus on developing effective combinations involving avutometinib and other targeted agents, Verastem aims to enhance the treatment landscape for patients with limited options and challenging prognoses. The company's research endeavors are driven by a persistent commitment to improving patient outcomes and expanding possibilities within the oncology space. Generated from the website

United Therapeutics Corp, based in Wellesley Hills, MA, is a biopharmaceutical company dedicated to the development and commercialization of unique products to address the unmet needs of patients with chronic and life-threatening conditions. The company focuses on creating innovative therapeutic solutions, particularly in the areas of pulmonary arterial hypertension and organ transplantation. With a commitment to advancing medical science and improving patient outcomes, United Therapeutics is continually engaged in research and development activities aimed at expanding its product portfolio. The company's mission reflects a dedication to enhancing the lives of patients by offering novel treatments that can significantly impact their health and wellbeing. Generated from the website

NightHawk Biosciences, based in Wellesley Hills, is a cutting-edge biotech company focused on developing innovative drugs that harness natural biological processes. Their primary goal is to activate and stimulate T-cells effectively, transforming cold tumors into hot ones. With a strong emphasis on leveraging the body's own mechanisms, NightHawk Biosciences at Heat Biologics is at the forefront of revolutionizing cancer treatment through their groundbreaking drug development approach. Their commitment to turning the tide against cancer is evident in their dedication to unlocking the potential of T-cell activation. Generated from their website's infomation